A Phase 1 interventional study of Clopidogrel and LY2216684 in Major Depressive Disorder, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-22.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing edivoxetine in Depressive Disorder, Major — none open to participants now, none under way, none of them phase 3. edivoxetine · Depressive Disorder, Major.
Among the 24 studies testing edivoxetine in Depressive Disorder, Major, this one is the 10th largest by enrollment, is one of 11 that started in 2010, is one of 15 in phase 1, and was the 11th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →None of the 24 studies testing edivoxetine in Depressive Disorder, Major is open now. The open studies under Depressive Disorder, Major, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 3 · Phase 3 7
First in 2006; this study’s year is marked. 11 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 47 is below the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 29 across the 24 interventional studies. Of the 24 that completed or were terminated, 24 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 24 have an industry lead sponsor. The 1 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
59 studies in Depressive Disorder, Major by Eli Lilly and Company: 3 open now, 3 under way, 2 of them phase 3. Of 55 finished, 42 (76%) have results posted.
Among the 59 studies in Depressive Disorder, Major by Eli Lilly and Company, this one is the 40th largest by enrollment of the 55 interventional ones that give a count, is one of 14 that started in 2010, is one of 17 in phase 1, and was the 39th registered.
Eli Lilly and Company’s Depressive Disorder, Major studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 24 studies testing edivoxetine in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 59 in Depressive Disorder, Major:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to measure how much of the study drugs (clopidogrel and LY2216684) reach the blood stream and how long it takes the body to dispose of them and to determine how clopidogrel and LY2216684 might affect each other in the body. Information about any side effects that may occur will also be collected.
Clopidogrel is rapidly converted to R-130964 by the enzyme cytochrome P450 2C19 (CYP2C19). Enrollment in the study was limited to participants with specific genotypes of the CYP2C19 gene, including the *1/*1 genotype (CYP2C19 extensive metabolizers) and the *1/*17 or *17/*17 genotypes (CYP2C19 ultra-rapid metabolizers). All primary and secondary objectives were limited to participants with the CYP2C19*1/*1 genotype.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1: a single 300-milligram (mg) dose of clopidogrel administered orally on Day 1 (Treatment 1). Period 2: an 18-mg dose of LY2216684 administered orally, once daily (QD) on Days 1 through 3, plus a single 300-mg dose of clopidogrel administered orally on Day 3 (Treatment 2). There was a washout period of at least 14 days between the last dose of study drug in Period 1 and the first dose in Period 2.
Drug: Clopidogrel · Drug: LY2216684
Period 1: an 18-milligram (mg) dose of LY2216684 administered orally, once daily (QD) on Days 1 through 3, plus a single 300-mg dose of clopidogrel administered orally on Day 3 (Treatment 2). Period 2: a single 300-mg dose of clopidogrel administered orally on Day 1 (Treatment 1). There was a washout period of at least 14 days between the last dose of study drug in Period 1 and the first dose in Period 2.
Drug: Clopidogrel · Drug: LY2216684
Pharmacokinetics of R-130964, Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-∞)
R-130964 is the active metabolite of clopidogrel. Blood samples were collected prior to and through 24 hours after administration of clopidogrel alone and in combination with LY2216684.
Time frame: predose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, and 24 hours postdose
Pharmacokinetics of R-130964, Area Under the Concentration-time Curve From Time 0 to Time of Last Measurable Concentration (AUC0-tlast)
R-130964 is the active metabolite of clopidogrel. Blood samples were collected prior to and through 24 hours after administration of clopidogrel alone and in combination with LY2216684. Log-transformed AUC0-tlast was analyzed using a linear mixed effects model with sequence, period, and treatment as fixed effects and participant as a random effect.
Time frame: predose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, and 24 hours postdose
Pharmacokinetics of R-130964, Maximum Observed Drug Concentrations (Cmax)
R-130964 is the active metabolite of clopidogrel. Blood samples were collected prior to and through 24 hours after administration of clopidogrel alone and in combination with LY2216684. Log-transformed Cmax was analyzed using a linear mixed effects model with sequence, period, and treatment as fixed effects and participant as a random effect.
Time frame: predose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, and 24 hours postdose
Pharmacokinetics of R-130964, Time to Maximum Observed Drug Concentrations (Tmax)
R-130964 is the active metabolite of clopidogrel. Blood samples were collected prior to and through 24 hours after administration of clopidogrel alone and in combination with LY2216684.
Time frame: predose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, and 24 hours postdose
Percentage Inhibition of Platelet Aggregation
Blood samples for the measurement of platelet aggregation using a point-of-care device, Accumetrics VerifyNow™ P2Y12 (VN-P2Y12), were collected prior to and through 24 hours after administration of clopidogrel alone and in combination with LY2216684. Device-reported percent inhibition of VN-P2Y12 (IPRU) is presented.
Time frame: predose and 2, 4, and 24 hours postdose
| Milestone | Clopidogrel First, Then LY2216684 + Clopidogrel | LY2216684 + Clopidogrel First, Then Clopidogrel |
|---|---|---|
| Started | 24 | 23 |
| Completed | 24 | 23 |
| Not completed | 0 | 0 |
| Milestone | Clopidogrel First, Then LY2216684 + Clopidogrel | LY2216684 + Clopidogrel First, Then Clopidogrel |
|---|---|---|
| Started | 24 | 23 |
| Completed | 23 | 23 |
| Not completed | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 |
| Milestone | Clopidogrel First, Then LY2216684 + Clopidogrel | LY2216684 + Clopidogrel First, Then Clopidogrel |
|---|---|---|
| Started | 23 | 23 |
| Completed | 22 | 23 |
| Not completed | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
R-130964 is the active metabolite of clopidogrel. Blood samples were collected prior to and through 24 hours after administration of clopidogrel alone and in combination with LY2216684.
| hours*nanograms/milliliters (h*ng/mL) | Clopidogrel | LY2216684 + Clopidogrel |
|---|---|---|
| Pharmacokinetics of R-130964, Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-∞) | 61.8 ± 50 | 55.3 ± 44 |
R-130964 is the active metabolite of clopidogrel. Blood samples were collected prior to and through 24 hours after administration of clopidogrel alone and in combination with LY2216684. Log-transformed AUC0-tlast was analyzed using a linear mixed effects model with sequence, period, and treatment as fixed effects and participant as a random effect.
| hours*nanograms/milliliters (h*ng/mL) | Clopidogrel | LY2216684 + Clopidogrel |
|---|---|---|
| Pharmacokinetics of R-130964, Area Under the Concentration-time Curve From Time 0 to Time of Last Measurable Concentration (AUC0-tlast) | 60.5 ± 45 | 46.9 ± 41 |
R-130964 is the active metabolite of clopidogrel. Blood samples were collected prior to and through 24 hours after administration of clopidogrel alone and in combination with LY2216684. Log-transformed Cmax was analyzed using a linear mixed effects model with sequence, period, and treatment as fixed effects and participant as a random effect.
| nanograms/milliliter (ng/mL) | Clopidogrel | LY2216684 + Clopidogrel |
|---|---|---|
| Pharmacokinetics of R-130964, Maximum Observed Drug Concentrations (Cmax) | 37.6 ± 56 | 22.7 ± 53 |
Blood samples for the measurement of platelet aggregation using a point-of-care device, Accumetrics VerifyNow™ P2Y12 (VN-P2Y12), were collected prior to and through 24 hours after administration of clopidogrel alone and in combination with LY2216684. Device-reported percent inhibition of VN-P2Y12 (IPRU) is presented.
| IPRU | Clopidogrel | LY2216684 + Clopidogrel |
|---|---|---|
| Predose | 1.7 ± 3.2 | 1.4 ± 3.2 |
| 2 Hours Postdose | 16.0 ± 20.3 | 7.6 ± 12.3 |
| 4 Hours Postdose | 30.4 ± 21.8 | 14.0 ± 16.6 |
| 24 Hours Postdose | 25.1 ± 21.1 | 14.3 ± 17.5 |
R-130964 is the active metabolite of clopidogrel. Blood samples were collected prior to and through 24 hours after administration of clopidogrel alone and in combination with LY2216684.
| hours | Clopidogrel | LY2216684 + Clopidogrel |
|---|---|---|
| Pharmacokinetics of R-130964, Time to Maximum Observed Drug Concentrations (Tmax) | 1.50 (1.00 to 2.07) | 1.50 (0.50 to 4.00) |
Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Clopidogrel | — | 0/47 (0%) | 12/47 (25.5%) |
| LY2216684 | — | 0/46 (0%) | 19/46 (41.3%) |
| LY2216684 + Clopidogrel | — | 0/45 (0%) | 11/45 (24.4%) |
| Event | Clopidogrel | LY2216684 | LY2216684 + Clopidogrel |
|---|---|---|---|
| NauseaGastrointestinal disorders | 1/47 | 7/46 | 2/45 |
| SomnolenceNervous system disorders | 0/47 | 7/46 | 0/45 |
| HeadacheNervous system disorders | 6/47 | 1/46 | 1/45 |
| Urinary hesitationRenal and urinary disorders | 0/47 | 4/46 | 0/45 |
| InsomniaPsychiatric disorders | 0/47 | 3/46 | 3/45 |
| RashSkin and subcutaneous tissue disorders | 0/47 | 1/46 | 3/45 |
| Abdominal painGastrointestinal disorders | 0/47 | 3/46 | 0/45 |
| VomitingGastrointestinal disorders | 0/47 | 3/46 | 0/45 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/47 | 0/46 | 0/45 |
| ChillsGeneral disorders | 2/47 | 1/46 | 2/45 |
All enrolled participants.
| Age, Continuous(years) | Clopidogrel First, Then LY2216684 + Clopidogrel | LY2216684 + Clopidogrel First, Then Clopidogrel | Total |
|---|---|---|---|
| Mean | 40.7 ± 11.2 | 44.5 ± 11.5 | 42.5 ± 11.4 |
| Sex: Female, Male(Participants) | Clopidogrel First, Then LY2216684 + Clopidogrel | LY2216684 + Clopidogrel First, Then Clopidogrel | Total |
|---|---|---|---|
| Female | 10 | 12 | 22 |
| Male | 14 | 11 | 25 |
| Ethnicity (NIH/OMB)(Participants) | Clopidogrel First, Then LY2216684 + Clopidogrel | LY2216684 + Clopidogrel First, Then Clopidogrel | Total |
|---|---|---|---|
| Hispanic or Latino | 16 | 12 | 28 |
| Not Hispanic or Latino | 8 | 11 | 19 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Clopidogrel First, Then LY2216684 + Clopidogrel | LY2216684 + Clopidogrel First, Then Clopidogrel | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 5 | 9 |
| White | 20 | 18 | 38 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Clopidogrel First, Then LY2216684 + Clopidogrel | LY2216684 + Clopidogrel First, Then Clopidogrel | Total |
|---|---|---|---|
| United States | 24 | 23 | 47 |
The record gives a start of Dec 2010, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2018, 7 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Clopidogrel · Edivoxetine